Glioblastoma (GBM)NCT07616986
LITT for Ultra-early GBM Recurrence
A study testing LITT in people with Glioblastoma (GBM) and Glioblastoma - Category, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
Trial summary
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glioblastoma (GBM), Glioblastoma - Category
- What is being tested?
- LITT
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteSwitzerland
- Study dates
- 6 Feb 2026to 31 Jan 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status
- ≥18 years of age
- CRET
- Karnofsky Performance Status (KPS) ≥70
- No contra-indication for radio-chemotherapy
- Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern
Show all 12Show fewer
- Able to provide informed consent
- No contra-indication for LITT
- No pregnancy or active breast-feeding
- No known coagulopathy independent of medication
- No dissemination or multifocal disease
- Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Dep. of Neurosurgery, Bern University Hospital
Bern, 3010
Alexis Terrapon, MD
About this study
Official title: Laser Interstitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy.
LITT offers a minimally invasive alternative that may:
- Treat recurrence without delaying RT/CT
- Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.
Read the detailed description
Background:
GBM is frequent and still has a poor prognosis. Standard therapy consists of complete resection of enhancing tumor (CRET) followed by RT and CT. At the institution, patients planned for RT undergo a pre-radiotherapy planning MRI. As recently published, >40% of patients exhibit contrast-enhancing tumor recurrence in the short interval between early postoperative MRI and pre-RT MRI, despite CRET in the initial surgery. This ultra-early recurrence is strongly associated with shorter OS: in the cohort, median overall survival (OS) was 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Hence, pre-radiation GBM recurrence is a frequent event with detrimental consequences for patients.
Reoperation in this setting is rarely performed as it delays adjuvant treatment, which worsen prognosis further. LITT is an established, minimally invasive treatment form for brain lesions such as glioblastoma recurrences and metastases. LITT may offer a solution to this dilemma as its minimal invasiveness enables to ablate the recurrent tumor without delaying treatment. As an additional benefit, LITT may work as a potent sensitizer to subsequent RT and CT.
A key challenge in the implementation of LITT in this setting is the tight scheduling window (maximum 1 week) between pre-radiotherapy planning MRI and start of radiotherapy. In order not to delay adjuvant treatment, LITT should optimally be performed within this time window. To be feasible, both planning and execution of LITT, including coordination of intraoperative MRI and engineering support, must occur within this short timeframe. This feasibility study aims to prospectively investigate whether LITT can be integrated into the existing care pathway without postponing of adjuvant treatment. This may lay the groundwork for future clinical trials.
Objective:
The aim is to test feasibility of integrating scheduling, planning and execution of LITT into the standard treatment course of patients with CRET-resected glioblastoma scheduled to receive concomitant radio-chemotherapy. The primary objective of this feasibility study is to evaluate the feasibility of performing LITT for ultra-early recurrence following GBM resection without delaying adjuvant radio-chemotherapy.
Secondary objectives are collected to estimate the effect size of pre-RT LITT on median overall survival compared to patients with ultra-early recurrence who do not receive LITT, and to historic controls; the purpose of these endpoints is to guide power calculations of a subsequent phase II trial.
Methods:
This is a prospective, single-arm, monocentric feasibility study conducted at the University Department of Neurosurgery, Inselspital, Bern. The study is exploratory in nature and aims to generate foundational data for a larger, multi-centric phase II trial. At the University Hospital of Bern, all patients are presented to the tumor board after surgery for brain tumors. All patients with histologically confirmed glioblastoma and without residual contrast enhancement (CRET) meeting the inclusion criteria for study participation will be asked for consent and, where applicable, included in the trial. All patients showing ultra-early recurrence on planning MRI and meeting the inclusion criteria for LITT will be considered to undergo LITT before the beginning of radiotherapy. Patients without recurrence ("no recurrence" group) and patients with recurrence who do not undergo LITT ("recurrence/no LITT" group) will serve as internal control groups.
- Conditions
- Glioblastoma (GBM), Glioblastoma - Category
- Being tested
- LITT
- Keywords
- LITT, Laser Interstitial Thermal Therapy, ultra-early recurrence, GMB, GMB recurrence, GMB ultra-early recurrence
- Medical subject headings
- Glioblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LITTDevice
Patients undergoing MR-guided Laser Interstitial Thermal Therapy (LITT) between pre-RT MRI and RT.
| Study group | Role | What they receive |
|---|---|---|
| LITT Group | Experimental | Patients undergoing MR-guided Laser Interstitial Thermal Therapy (LITT) between pre-RT MRI and RT Receives: Device: LITT |
| Control Group 1 ("No recurrence") | No intervention | Patients with no recurrence on pre-RT MRI, proceeding directly to RT. |
| Control Group 2 ("No LITT") | No intervention | Patients with recurrence but ineligible for LITT, proceeding to another resection or to RT without laser therapy. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of patients who successfully complete the planned treatment
Proportion of CRET patients who successfully complete the planned treatment protocol without protocol violation, until the end of radiation therapy. A protocol violation is defined as any of the following: a delay of more than 7 days in the scheduled pre-RT MRI, LITT procedure, or RT initiation, or an interruption of RT due to a LITT-related event. The study teams aims to describe logistical and organizational difficulties (coordination of intraoperative MRI-availability, engineering support).
Measured: from enrollment to the end of radiotherapy, an average of 8 weeks
Secondary outcomes (14)
Complications of LITT
Any deviation from the normal postoperative course, including any new appearance of blood during LITT MRI, any seeding along the trajectory of the probe, any pathological wound condition such as dehiscence or infection
Measured: from enrollment to the end of radiotherapy, an average of 8 weeks
Delay of Radiotherapy
Measurement of the time-lag between planning MRI and beginning of radiation, and comparsion to pre-planned radiation start
Measured: assessed the day of radiation start, ranging from 3 to 6 weeks after GBM resection
Use of steroids
Use of steroids: Binary (yes/no) and, if applicable, dose and duration
Measured: from enrollment to the end of radiotherapy, an average of 8 weeks
Evolution of radiation necrosis
Any increase of the size of the contrast enhancing lesion
Measured: from enrollment to the end of radiotherapy, an average of 8 weeks
Evolution of target lesion
Any increase of the size of the contrast enhancing lesion
Measured: from enrollment to the end of radiotherapy, an average of 8 weeks
Evolution of pseudoprogression
Any increase of the size of the contrast enhancing lesion
Measured: from enrollment to the end of radiotherapy, an average of 8 weeks
Time to local recurrence
Time from detection of relapse to detection of local glioblastoma recurrence (lesion within/at the borders of the surgical cavity or associated FLAIR/T2 hyperintensity)
Measured: from enrollment to the end of radiotherapy, an average of 8 weeks
Time to distant recurrence
Time from detection of relapse to detection of distant glioblastoma recurrence (outside the borders of the surgical cavity or associated FLAIR/T2 hyperintensity)
Measured: from enrollment to the end of radiotherapy, an average of 8 weeks
Median overall survival
Median overall survival measured from first surgery to death
Measured: from enrollment to date of death, assessed up to the end of the study period (end of ratiotherapy for the last included patient)
Site of recurrence
Spatial position of the recurrence (local adjacent, distant)
Measured: assessed the day of radiation start, ranging from 3 to 6 weeks after GBM resection
Recruitment rate
Proportion of CRET patients who agree to participate
Measured: at study completion (date of end of radiotherapy for the last included patient, approximately 2 years after enrollment of the first participant
Progression rate
Proportion of recruited patients who present with progression on pre-RT MRI
Measured: pre RT-MRI
Inclusion rate
Rate of recruited patients who agree to receiving LITT
Measured: pre RT-MRI
Treatment rate
Rate of recruited patients who receive LITT
Measured: at study completion (date of end of radiotherapy for the last included patient, approximately 2 years after enrollment of the first participant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jun 2026
- Study start6 Feb 2026
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Glioblastoma (GBM)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Philippe Schucht, MD, Principal investigator, Inselspital Bern, Department of Neurosurgery
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07616986
- Sponsor's protocol ID
- 2025-01709
- Other IDs
- 2025
- Status last verified
- May 2026
- First submitted
- 24 Nov 2025
- Last updated
- 1 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Terrapon APR, Zattra CM, Voglis S, Velz J, Vasella F, Akeret K, Held U, Schiavolin S, Bozinov O, Ferroli P, Broggi M, Sarnthein J, Regli L, Neidert MC. Adverse Events in Neurosurgery: The Novel Therapy-Disability-Neurology Grade. Neurosurgery. 2021 Jul 15;89(2):236-245. doi: 10.1093/neuros/nyab121.
PubMed 33887774Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023 Feb 21;329(7):574-587. doi: 10.1001/jama.2023.0023.
PubMed 36809318Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330.
PubMed 15758009Waqar M, Roncaroli F, Lehrer EJ, Palmer JD, Villanueva-Meyer J, Braunstein S, Hall E, Aznar M, De Witt Hamer PC, D'Urso PI, Trifiletti D, Quinones-Hinojosa A, Wesseling P, Borst GR. Rapid early progression (REP) of glioblastoma is an independent negative prognostic factor: Results from a systematic review and meta-analysis. Neurooncol Adv. 2022 Jun 4;4(1):vdac075. doi: 10.1093/noajnl/vdac075. eCollection 2022 Jan-Dec.
PubMed 35769410McGrath K, Frain M, Hey G, Rahman M. Complications following laser interstitial thermal therapy: a review. Neurochirurgie. 2025 Jan;71(1):101604. doi: 10.1016/j.neuchi.2024.101604. Epub 2024 Oct 23.
PubMed 39413572Rangwala HS, Shafique MA, Mustafa MS, Kumar R, Devi J, Rangwala BS, Ali SMS, Raja A, Iqbal J, Ali M, Haseeb A. Evaluating efficacy and safety of laser interstitial thermal therapy in patients with newly diagnosed and recurrent glioblastoma: a systematic review and meta-analysis. Neurosurg Rev. 2024 Nov 12;47(1):846. doi: 10.1007/s10143-024-03077-6.
PubMed 39528836Yu JS, Meade SM, Zhao R, Wei W, Dashora H, Prayson R, Grabowski MM, Stevens G, Lobbous M, Murphy ES, Suh JH, Chao ST, Barnett GH, Peereboom D, Ahluwalia MS, Mohammadi AM. Expedited chemoradiation after laser interstitial thermal therapy (LITT) is feasible and safe in patients with newly diagnosed glioblastoma. Neurooncol Adv. 2025 Feb 14;7(1):vdaf038. doi: 10.1093/noajnl/vdaf038. eCollection 2025 Jan-Dec.
PubMed 40276375Hani L, Hakim A, Gehrig L, Staruch M, Goldberg J, Russli S, Soll N, Raabe A, Ermis E, Schucht P. Identification and relevance of ultra-early progression after resection of glioblastoma. J Neurosurg. 2025 Jul 25;143(5):1315-1324. doi: 10.3171/2025.3.JNS242212. Print 2025 Nov 1.
PubMed 40712164
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Laser Interstitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence
- ClinicalTrials.gov ID
- NCT07616986
- Acronym / sponsor ID
- 2025-01709
- Conditions
- Glioblastoma (GBM), Glioblastoma - Category
- Keywords
- LITT, Laser Interstitial Thermal Therapy, ultra-early recurrence, GMB, GMB recurrence, GMB ultra-early recurrence
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Insel Gruppe AG, University Hospital BernUniversity, hospital or other
- Study start
- 6 Feb 2026 (actual)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Jan 2028 (estimated)
- First posted
- 1 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy.
LITT offers a minimally invasive alternative that may:
- Treat recurrence without delaying RT/CT
- Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.
Detailed description
Background:
GBM is frequent and still has a poor prognosis. Standard therapy consists of complete resection of enhancing tumor (CRET) followed by RT and CT. At the institution, patients planned for RT undergo a pre-radiotherapy planning MRI. As recently published, >40% of patients exhibit contrast-enhancing tumor recurrence in the short interval between early postoperative MRI and pre-RT MRI, despite CRET in the initial surgery. This ultra-early recurrence is strongly associated with shorter OS: in the cohort, median overall survival (OS) was 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Hence, pre-radiation GBM recurrence is a frequent event with detrimental consequences for patients.
Reoperation in this setting is rarely performed as it delays adjuvant treatment, which worsen prognosis further. LITT is an established, minimally invasive treatment form for brain lesions such as glioblastoma recurrences and metastases. LITT may offer a solution to this dilemma as its minimal invasiveness enables to ablate the recurrent tumor without delaying treatment. As an additional benefit, LITT may work as a potent sensitizer to subsequent RT and CT.
A key challenge in the implementation of LITT in this setting is the tight scheduling window (maximum 1 week) between pre-radiotherapy planning MRI and start of radiotherapy. In order not to delay adjuvant treatment, LITT should optimally be performed within this time window. To be feasible, both planning and execution of LITT, including coordination of intraoperative MRI and engineering support, must occur within this short timeframe. This feasibility study aims to prospectively investigate whether LITT can be integrated into the existing care pathway without postponing of adjuvant treatment. This may lay the groundwork for future clinical trials.
Objective:
The aim is to test feasibility of integrating scheduling, planning and execution of LITT into the standard treatment course of patients with CRET-resected glioblastoma scheduled to receive concomitant radio-chemotherapy. The primary objective of this feasibility study is to evaluate the feasibility of performing LITT for ultra-early recurrence following GBM resection without delaying adjuvant radio-chemotherapy.
Secondary objectives are collected to estimate the effect size of pre-RT LITT on median overall survival compared to patients with ultra-early recurrence who do not receive LITT, and to historic controls; the purpose of these endpoints is to guide power calculations of a subsequent phase II trial.
Methods:
This is a prospective, single-arm, monocentric feasibility study conducted at the University Department of Neurosurgery, Inselspital, Bern. The study is exploratory in nature and aims to generate foundational data for a larger, multi-centric phase II trial. At the University Hospital of Bern, all patients are presented to the tumor board after surgery for brain tumors. All patients with histologically confirmed glioblastoma and without residual contrast enhancement (CRET) meeting the inclusion criteria for study participation will be asked for consent and, where applicable, included in the trial. All patients showing ultra-early recurrence on planning MRI and meeting the inclusion criteria for LITT will be considered to undergo LITT before the beginning of radiotherapy. Patients without recurrence ("no recurrence" group) and patients with recurrence who do not undergo LITT ("recurrence/no LITT" group) will serve as internal control groups.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| LITT Group | Experimental | Device: LITTPatients undergoing MR-guided Laser Interstitial Thermal Therapy (LITT) between pre-RT MRI and RT |
| Control Group 1 ("No recurrence") | No intervention | –Patients with no recurrence on pre-RT MRI, proceeding directly to RT. |
| Control Group 2 ("No LITT") | No intervention | –Patients with recurrence but ineligible for LITT, proceeding to another resection or to RT without laser therapy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status
- ≥18 years of age
- CRET
- Karnofsky Performance Status (KPS) ≥70
- No contra-indication for radio-chemotherapy
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LITTPatients undergoing MR-guided Laser Interstitial Thermal Therapy (LITT) between pre-RT MRI and RT. | Device | LITT Group |
Primary outcome
Rate of patients who successfully complete the planned treatment
Time frame: from enrollment to the end of radiotherapy, an average of 8 weeks
Proportion of CRET patients who successfully complete the planned treatment protocol without protocol violation, until the end of radiation therapy. A protocol violation is defined as any of the following: a delay of more than 7 days in the scheduled pre-RT MRI, LITT procedure, or RT initiation, or an interruption of RT due to a LITT-related event. The study teams aims to describe logistical and organizational difficulties (coordination of intraoperative MRI-availability, engineering support).
14 secondary outcomes
Complications of LITT
Time frame: from enrollment to the end of radiotherapy, an average of 8 weeks
Delay of Radiotherapy
Time frame: assessed the day of radiation start, ranging from 3 to 6 weeks after GBM resection
Use of steroids
Time frame: from enrollment to the end of radiotherapy, an average of 8 weeks
Evolution of radiation necrosis
Time frame: from enrollment to the end of radiotherapy, an average of 8 weeks
Evolution of target lesion
Time frame: from enrollment to the end of radiotherapy, an average of 8 weeks
Evolution of pseudoprogression
Time frame: from enrollment to the end of radiotherapy, an average of 8 weeks
Time to local recurrence
Time frame: from enrollment to the end of radiotherapy, an average of 8 weeks
Time to distant recurrence
Time frame: from enrollment to the end of radiotherapy, an average of 8 weeks
Median overall survival
Time frame: from enrollment to date of death, assessed up to the end of the study period (end of ratiotherapy for the last included patient)
Site of recurrence
Time frame: assessed the day of radiation start, ranging from 3 to 6 weeks after GBM resection
Recruitment rate
Time frame: at study completion (date of end of radiotherapy for the last included patient, approximately 2 years after enrollment of the first participant
Progression rate
Time frame: pre RT-MRI
Inclusion rate
Time frame: pre RT-MRI
Treatment rate
Time frame: at study completion (date of end of radiotherapy for the last included patient, approximately 2 years after enrollment of the first participant
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2026.
- Background: PubMed 33887774Terrapon APR, Zattra CM, Voglis S, Velz J, Vasella F, Akeret K, Held U, Schiavolin S, Bozinov O, Ferroli P, Broggi M, Sarnthein J, Regli L, Neidert MC. Adverse Events in Neurosurgery: The Novel Therapy-Disability-Neurology Grade. Neurosurgery. 2021 Jul 15;89(2):236-245. doi: 10.1093/neuros/nyab121.
- Background: PubMed 36809318Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023 Feb 21;329(7):574-587. doi: 10.1001/jama.2023.0023.
- Background: PubMed 15758009Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330.
- Background: PubMed 35769410Waqar M, Roncaroli F, Lehrer EJ, Palmer JD, Villanueva-Meyer J, Braunstein S, Hall E, Aznar M, De Witt Hamer PC, D'Urso PI, Trifiletti D, Quinones-Hinojosa A, Wesseling P, Borst GR. Rapid early progression (REP) of glioblastoma is an independent negative prognostic factor: Results from a systematic review and meta-analysis. Neurooncol Adv. 2022 Jun 4;4(1):vdac075. doi: 10.1093/noajnl/vdac075. eCollection 2022 Jan-Dec.
- Background: PubMed 39413572McGrath K, Frain M, Hey G, Rahman M. Complications following laser interstitial thermal therapy: a review. Neurochirurgie. 2025 Jan;71(1):101604. doi: 10.1016/j.neuchi.2024.101604. Epub 2024 Oct 23.
- Background: PubMed 39528836Rangwala HS, Shafique MA, Mustafa MS, Kumar R, Devi J, Rangwala BS, Ali SMS, Raja A, Iqbal J, Ali M, Haseeb A. Evaluating efficacy and safety of laser interstitial thermal therapy in patients with newly diagnosed and recurrent glioblastoma: a systematic review and meta-analysis. Neurosurg Rev. 2024 Nov 12;47(1):846. doi: 10.1007/s10143-024-03077-6.
- Background: PubMed 40276375Yu JS, Meade SM, Zhao R, Wei W, Dashora H, Prayson R, Grabowski MM, Stevens G, Lobbous M, Murphy ES, Suh JH, Chao ST, Barnett GH, Peereboom D, Ahluwalia MS, Mohammadi AM. Expedited chemoradiation after laser interstitial thermal therapy (LITT) is feasible and safe in patients with newly diagnosed glioblastoma. Neurooncol Adv. 2025 Feb 14;7(1):vdaf038. doi: 10.1093/noajnl/vdaf038. eCollection 2025 Jan-Dec.
- Background: PubMed 40712164Hani L, Hakim A, Gehrig L, Staruch M, Goldberg J, Russli S, Soll N, Raabe A, Ermis E, Schucht P. Identification and relevance of ultra-early progression after resection of glioblastoma. J Neurosurg. 2025 Jul 25;143(5):1315-1324. doi: 10.3171/2025.3.JNS242212. Print 2025 Nov 1.
Related trials for Glioblastoma (GBM)
Not yet recruiting
A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated
Newly Diagnosed Glioblastoma, MGMT-Unmethylated Glioblastoma
Active, not recruitingPhase 1/2
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Glioblastoma, Gliosarcoma
RecruitingPhase 2
Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
Glioblastoma, IDH-Wildtype
Active, not recruitingPhase 1
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
Glioblastoma
Active, not recruitingPhase 2
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Philippe Schucht, MD principal investigator
Inselspital Bern, Department of Neurosurgery
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing LITT in people with Glioblastoma (GBM) and Glioblastoma - Category, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Philippe Schucht, MD (+41 31 632 00 14, philippe.schucht@insel.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of patients who successfully complete the planned treatment (time frame: from enrollment to the end of radiotherapy, an average of 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07616986, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026.